US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Global Migraine Epidemiology and Patient Flow Analysis - 2015
1/9/2015 | published by: Fore Pharma
... report provides insights into Migraine epidemiology, Migraine diagnosed patients, and Migraine treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Migraine derived from epidemiological analysis, percentage of patients ...  |  read more...
USD 1,200
Bipolar Disorder (Manic Depression)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Bipolar Disorder (Manic Depression). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Obsessive-Compulsive Disorder-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Obsessive-Compulsive Disorder. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Schizophrenia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Schizophrenia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Schizophrenia. ...  |  read more...
USD 2,000
Amyotrophic Lateral Sclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Amyotrophic Lateral Sclerosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Dementia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Dementia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Dementia. ...  |  read more...
USD 2,000
Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Fibromyalgia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Fibromyalgia. ...  |  read more...
USD 2,000
Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Glioblastoma Multiforme (GBM). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Glioma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Glioma. ...  |  read more...
USD 2,000
Medulloblastoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Medulloblastoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Medulloblastoma. ...  |  read more...
USD 2,000
Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Metastatic Brain Tumor. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Narcolepsy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Narcolepsy. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Narcolepsy. ...  |  read more...
USD 2,000
Virtual Reality in Healthcare Market, Markets for Remote Surgery, 3D Modeling, Pain Distraction and Other Applications) Global Industry Analysis, Size, Share, Demand, Future, Growth, Trends, Opportunities (Psychology, Radiology, Oncology) Segmentation And
2/6/2015 | published by: Occams Business Research & Consultancy
... Reality technology is a computer-simulated environment that can recreate sensory experiences and stimulate presence in locations that are from the real world or may be from an imagined world. It has generated tremendous excitement in ...  |  read more...
USD 2,800
Global Schizophrenia Epidemiology and Patient Flow Analysis - 2015
1/9/2015 | published by: Fore Pharma
... report provides insights into Schizophrenia epidemiology, Schizophrenia diagnosed patients, and Schizophrenia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Schizophrenia derived from epidemiological analysis, percentage of patients ...  |  read more...
USD 1,200
Brain Cancer Drug Pipeline Update 2015
1/5/2015 | published by: BioSeeker Group AB
... primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are today 224 companies plus partners developing 276 ...  |  read more...
USD 6,746
Traumatic Brain Injury: Therapeutic and Diagnostic Pipeline Assessment and Commercial Prospects
10/21/2014 | published by: Arrowhead Publishers
... around 10 million new cases diagnosed and 1.5 million deaths occurring per annum globally; this ‘silent’ epidemic accounts for more fatalities than diabetes or lung cancer. Despite three decades of intensive research and development effort, ...  |  read more...
USD 1,750
Assistive Technology for People with Dementia
11/26/2014 | published by: Emerald Group Publishing Limited
... address a small sample of various everyday life needs – use of information and communication technology, reminders on carrying out tasks, being safe and able to communicate with carers when out of the home, and, ...  |  read more...
USD 199
Global and Chinese Milnacipran Industry, 2009-2019 Market Research Report
9/17/2014 | published by: Prof-Research
... key statistics on the market status of the Milnacipran manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of ...  |  read more...
USD 2,800
Dementia Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
Depression Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. ...  |  read more...
USD 2,000
Recurrent Malignant Glioma-Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
... all the pipeline drugs that fall under Recurrent Malignant Glioma. This report provides information on the therapeutic development based on the Recurrent Malignant Glioma dealing with all the pipeline drugs, comparative analysis at various stages ...  |  read more...
USD 1,250
Intraoperative Neuromonitoring Market in the US 2015-2019
11/26/2014 | published by: TechNavio - Infiniti Research Ltd.
... be used in various surgical procedures including neurosurgery, vascular surgery, ENT surgery, orthopedic surgery, cardiac surgery, genitourinary surgery, interventional radiological procedures, and other general surgeries. It plays a vital role in surgery to provide immediate ...  |  read more...
USD 2,500
Optical Imaging Market by Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic Tomography), Product (Imaging System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts to 2019
10/17/2014 | published by: MarketsandMarkets
... optical imaging market has grown, primarily due to the widening applications of optical imaging techniques, the increased demand for safer and noninvasive imaging modalities, and a rising need to minimize the use of radiation in ...  |  read more...
USD 4,650
Treatment Resistant Depression - Pipeline Review, H2 2014
11/18/2014 | published by: Global Markets Direct
... information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
USD 2,000
Depression Pipeline Highlights – 2015
11/5/2014 | published by: Fore Pharma
... clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing ...  |  read more...
USD 670
3  4  5  6    8    10  11  12